Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: A single-dose, randomized, open-label, crossover study

Clinical Therapeutics

Volumn 32, Issue 2, 2010, Pages 252-264

  Boellner, Samuel W ^a   Stark, Jeffrey G ^b   Krishnan, Suma ^c   Zhang, Yuxin ^d  

^a Clinical Study Centers LLC   (United States)

^b CEDRA Corporation   (United States)

^c New River Pharmaceuticals   (United States)

^d Xtiers Consulting   (United States)

Author keywords

ADHD; LDX; pharmacokinetics; stimulant; Vyvanse

Indexed keywords

CEFPROZIL; CENTRAL STIMULANT AGENT; CETIRIZINE; DECONGESTIVE AGENT; DEXAMPHETAMINE; LISDEXAMFETAMINE; PARACETAMOL;

ABDOMINAL PAIN; ACADEMIC ACHIEVEMENT; AGE; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ATTENTION DEFICIT DISORDER; BODY WEIGHT; CAUCASIAN; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG FATALITY; DRUG HALF LIFE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NEGRO; OPEN STUDY; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; VITAL SIGN;

ADMINISTRATION, ORAL; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOTRANSFORMATION; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-OVER STUDIES; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PRODRUGS; TREATMENT OUTCOME;

EID: 77649101889     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.02.011     Document Type: Article

References (43)

1. Polanczyk G., de Lima M.S., Horta B.L., et al. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry 164 (2007) 942-948
2. Biederman J., and Faraone S.V. Attention-deficit hyperactivity disorder [published correction appears in Lancet. 2006;367:210]. Lancet 366 (2005) 237-248
3. Faraone S.V., Sergeant J., Gillberg C., and Biederman J. The worldwide prevalence of ADHD: Is it an American condition?. World Psychiatry 2 (2003) 104-113
4. Goldman L.S., Genel M., Bezman R.J., Slanetz P.J., Council on Scientific Affairs, and American Medical Association. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 279 (1998) 1100-1107
5. Cantwell D.P. Attention deficit disorder: A review of the past 10 years. J Am Acad Child Adolesc Psychiatry 35 (1996) 978-987
6. Greenhill L.L., Pliszka S., Dulcan M.K., et al., American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad ChildAdolesc Psychiatry 41 Suppl 2 (2002) 26S-49S
7. Pliszka S.R., Crismon M.L., Hughes C.W., et al., Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder. The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45 (2006) 642-657
8. Charach A., Figueroa M., Chen S., et al. Stimulant treatment over 5 years: Effects on growth. J Am Acad Child Adolesc Psychiatry 45 (2006) 415-421
9. Faraone S.V., Biederman J., Morley C.P., and Spencer T.J. Effect of stimulants on height and weight: A review of the literature. J Am Acad Child Adolesc Psychiatry 47 (2008) 994-1009
10. Safer D.J. Relative cardiovascular safety of psychostimulants used to treat attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2 (1992) 279-290
11. Findling R.L., Short E.J., and Manos M.J. Short-term cardiovascular effects of methylphenidate and Adderall. J Am Acad Child Adolesc Psychiatry 40 (2001) 525-529
12. Findling R.L., Biederman J., Wilens T.E., et al., SLI381.301 and.302 Study Groups. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr. 147 (2005) 348-354
13. Kollins S.H. ADHD, substance use disorders, and psychostimulant treatment: Current literature and treatment guidelines. J Atten Disord. 12 (2008) 115-125
14. Faraone S.V. Lisdexamfetamine dimesylate: The first longacting prodrug stimulant treatment for attention deficit/hyperactivity disorder. Expert Opin Pharmacother 9 (2008) 1565-1574
15. McGough J.J., Biederman J., Greenhill L.L., et al. Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall. J Am Acad Child Adolesc Psychiatry 42 (2003) 684-691
16. Vyvanse (lisdexamfetamine dimesylate) capsules [package insert] (2009), Shire US Inc, Wayne, Pa
17. Findling R.L., Ginsberg L.D., Jain R., and Gao J. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: An open-label, dose-optimization study. J Child Adolesc Psychopharmacol. 19 (2009) 649-662
18. Pennick M. Hydrolytic conversion of lisdexamfetamine dimesylate to the active moiety, d-amphetamine. Presented at: 64th Annual Scientific Convention & Meeting of the Society of Biological Psychiatry (May 14-16, 2009), British Columbia, Canada, Vancouver
19. Pennick M. Absorption of lisdexamfetamine dimesylate and hydrolysis to form the active moiety, d-amphetamine. Presented at: 49th Annual Meeting of the New Clinical Drug Evaluation Unit. Hollywood, Fla (June 29-July 2, 2009)
20. Shojaei A., Ermer J.C., and Krishnan S. Lisdexamfetamine dimesylate as a treatment for ADHD: Dosage formulation and pH effects. Presented at: 160th Annual Meeting of the American Psychiatric Association (May 19-24, 2007), Calif. Poster NR 740, San Diego
21. Krishnan S., and Zhang Y. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: A single-dose, crossover pharmacokinetic study. J Clin Pharmacol. 48 (2008) 293-302
22. Haffey M.B., Buckwalter M., Zhang P., et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med. 121 (2009) 11-19
23. Biederman J., Boellner S.W., Childress A., et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extendedrelease in children with ADHD: A double-blind, placebocontrolled, crossover analog classroom study. Biol Psychiatry 62 (2007) 970-976
24. Ermer J, Homolka R, Martin P, et al. Lisdexamfetamine dimesylate: Linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. J Clin Pharmacol. In press.
25. Wigal S.B., Kollins S.H., Childress A.C., Squires L., and 311 Study Group. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health 3 (2009) 17
26. Biederman J., Krishnan S., Zhang Y., et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A phase III, multicenter, randomized, doubleblind, forced-dose, parallel-group study. Clin Ther. 29 (2007) 450-463
27. Adler L.A., Goodman D.W., Kollins S.H., et al., 303 Study Group. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 69 (2008) 1364-1373
28. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/en/30publications/10policies/b3/index.html Accessed January 19, 2010
29. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R1). http://www.ich.org/LOB/media/MEDIA482.pdf Accessed January 19, 2010
30. US Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf Accessed January 19, 2010
31. US Food and Drug Administration. Guidance for Industry: Bioavailability and bioequivalence studies for orally administered drug productsgeneral considerations. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidelines/UCM070124.pdf Accessed August 8, 2009
32. Krishnan S.M., Pennick M., and Stark J.G. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: Open-label, single-centre, phase I study in healthy adult volunteers. Clin Drug Investig. 28 (2008) 745-755
33. Krishnan S.M., and Stark J.G. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr Med Res Opin. 24 (2008) 33-40
34. Markowitz J.S., Straughn A.B., Patrick K.S., et al. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet 42 (2003) 393-401
35. Tuerck D., Appel-Dingemanse S., Maboudian M., et al. Doseproportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. J Clin Pharmacol. 47 (2007) 64-69
36. Markowitz J.S., Straughn A.B., and Patrick K.S. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: Focus on methylphenidate formulations. Pharmacotherapy 23 (2003) 1281-1299
37. Adderall XR (mixed salts of a singleentity amphetamine product) [package insert] (2009), Shire US Inc, Wayne, Pa
38. Concerta (methylphenidate HCI) extended-release tablets [package insert] (2009), McNeil Pediatrics, Titusville, NJ
39. Focalin XR (dexmethylphenidate) extended-release tablets [package insert] (2009), Novartis Pharmaceuticals Corporation, East Hanover, NJ
40. Gualtieri C.T., Hicks R.E., Patrick K., et al. Clinical correlates of methylphenidate blood levels. Ther Drug Monit. 6 (1984) 379-392
41. Pichini S., Papaseit E., Joya X., et al. Pharmacokinetics and therapeutic drug monitoring of psychotropic drugs in pediatrics. Ther Drug Monit. 31 (2009) 283-318
42. Connor D.F., and Steingard R.J. New formulations of stimulants for attention-deficit hyperactivity disorder: Therapeutic potential. CNS Drugs. 18 (2004) 1011-1130
43. Gillberg C., Melander H., von Knorring A.L., et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, doubleblind, placebo-controlled trial. Arch Gen Psychiatry 54 (1997) 857-864